Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syntaxin's partner Allergan has begun two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868.
Subscribe to our email newsletter
The Phase II trials will evaluate the drug candidate in patients with post herpetic neuralgia (PHN) and overactive bladder.
AGN-214868 was discovered under the partnership using Syntaxin’s proprietary discovery platform.
Under the agreement, Allergan will be responsible for clinical development, marketing and sales of identified drug candidates, while Syntaxin will receive milestone payments and royalties on product sales.